Pulmonx
Pulmonx Corporation is a medical technology company specializing in minimally invasive solutions for the diagnosis and treatment of chronic obstructive pulmonary disease (COPD), particularly severe emphysema. Its primary offerings include the Zephyr Endobronchial Valve, designed for patients with hyperinflation due to emphysema, as well as the Chartis Pulmonary Assessment System, which assesses collateral ventilation, and the StratX Lung Analysis Platform, a cloud-based service that analyzes computed tomography data to identify suitable treatment areas. Pulmonx aims to improve the quality of life for patients who remain symptomatic despite medical management and may not be candidates for surgical interventions. The company has received FDA pre-market approval for the Zephyr Valve and has established a global presence, serving markets in the United States, Europe, the Middle East, Africa, and the Asia-Pacific region. Founded in 1995 and headquartered in Redwood City, California, Pulmonx has become a leader in interventional procedures for COPD, supported by extensive clinical evidence demonstrating the effectiveness of its technologies.
2 past transactions
Aeris Therapeutics
Acquisition in 2015
Aeris Therapeutics, Inc. is a medical therapeutics company focused on developing and commercializing innovative therapies for patients suffering from emphysema and other advanced lung diseases. The company offers the AeriSeal System, which aims to reduce lung volume and enhance lung function in patients with advanced emphysema. This system enables physicians to directly treat damaged lung areas using a bronchoscope. Established in 2000 and located in Woburn, Massachusetts, Aeris Therapeutics was formerly known as Bistech, Inc. and rebranded in February 2004. As of early 2015, Aeris Therapeutics operates as a subsidiary of Pulmonx Inc., maintaining a commitment to scientific excellence and high-quality standards in pulmonary medicine.
Emphasys Medical
Acquisition in 2009
Emphasys Medical is a medical device company based in Redwood City, California, specializing in the development of therapeutic devices for the treatment of emphysema and other chronic obstructive pulmonary diseases (COPD). Founded in 2000, the company focuses on minimally invasive therapies that aim to alleviate the symptoms associated with these respiratory conditions. Its flagship product, the Zephyr Endobronchial Valve system, is designed to block airflow through damaged lung tissue, facilitating healing and improving lung function. By offering innovative solutions for patients with emphysema, Emphasys Medical seeks to enhance the quality of life for individuals suffering from debilitating breathing disorders.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.